What did oncocyte corporation acquire from chronix biomedical? Oncocyte Corporation (NYSE: OCX) has agreed to acquire Chronix Biomedical, a privately held molecular diagnostics company, developing blood tests for cancer treatment and organ transplants. This agreement supersedes the previous agreement announced in October 2020.Is oncocyte tapping the stock market? Unfortunately, there are also... Cancer diagnostics specialist Oncocyte (NYSEMKT: OCX) rose at a double-digit pace on Friday on news that it's tapping the stock market for a new round of capital-raising. Oncocyte priced its previously announced underwritten secondary stock issue of 7.78 million shares at $4.50 apiece.Should you buy oncocyte ocx stock based on options moves? Investors need to pay close attention to OncoCyte (OCX) stock based on the movements in the options market lately.
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Com Read More. Headquarters: 15 Cushing, Irvine, California, 92618, United States.